Active Biotech Obtains US Patent for Cancer Product.Business Editors LUND, Sweden--(BUSINESS WIRE)--Feb. 6, 2002 The US patent office has issued a "Notice of Allowance" for Active Biotech's patent application regarding the prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. project. The patent includes product and methodological requirements designed to protect this form of prostate and breast cancer treatment This article or section recently underwent a major revision or rewrite and needs further review. You can help! The mainstay of breast cancer treatment is surgery when the tumor is localized, with possible adjuvant hormonal therapy (with tamoxifen or an aromatase . The patent also extends the protection already obtained by the company for its so-called Q-competence platform, which includes SAIK-MS (multiple sclerosis), among others. Active Biotech collaborates with Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. in Baltimore in the US with the aim of developing a drug for use in fighting prostate cancer. The collaboration has been successful and a final pharmaceutical candidate for clinical trials is expected to be selected shortly. Next step in the project will be to prepare the process of large-scale production, followed by a more in-depth safety evaluation. This will be performed ahead of the clinical evaluation clinical evaluation Medtalk An evaluation of whether a Pt has symptoms of a disease, is responding to treatment, or is having adverse reactions to therapy which is planned to begin during the first half of 2003. The aim of the project is to develop a product with an anti-tumour effect based on the substance's ability to prevent blood supply (angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. ) to the tumour, thus cutting off the tumour's supply of nutrients and oxygen. Prostate cancer is the most common form of cancer among men and accounts for almost one third of all cancers. The disease mainly affects men over 50 yeras of age. The severity of prostate cancer can vary considerably. Although the prognosis is relatively good, prostate cancer remains the form of cancer that causes most deaths among men in Sweden. The relative 10-year survival rate is around 50%. Active Biotech is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects (clinical trials phase II) include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases(SAIK SAIK Sandvikens Aik ), as well as a novel concept for use in cancer immunotherapy(TTS (1) See text-to-speech. (2) (Transaction Tracking System) Software that monitors a transaction until completion. In the event of a hardware or software failure, it ensures that the database is brought back to its former state before the attempt to ). For more info see www.activebiotech.com |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion